PMV Pharmaceuticals Inc. (NASDAQ:PMVP) currently has a daily average trading volume of 589.80K but it saw 943680 shares traded on Thursday. With a market cap of 265.73M USD, stock’s current market price of $5.70 came rising about 2.70 while comparing to the previous closing price of $5.55. In past 52 weeks, the stock remained buoying in the range of price level as high as $24.26 and as low as $5.09. In the recent trading on the day, stock has struck highest price mark of $5.88 while lowest mark touched by it was $5.30.
Will You Miss Out On This Growth Stock Boom?
A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.
And this is just one of our 5 Best Growth Stocks To Own For 2023.
Taking a look at 20-day trading activity of PMV Pharmaceuticals Inc. (PMVP) gives us an average price of $6.42, while its current price level is -76.51% below from 52-week high level whereas it is 11.98% above from lowest level seen by the stock during that period. Simple moving average of 50 days or SMA-50 of the stock’s closing price is $7.44 while that of 200 days or SMA-200 reads an average of $11.18. A closer look into the stock’s movement over the week reveals that its volatility is standing at 8.33% during that period while stretching the period over a month that decreases to 7.28%. It is also necessary to take a look into other indicators of a stock too, to get a better idea about its price movement. And in doing so, we find stock’s 14-day relative strength index (RSI) standing at 33.78 which implies that the stock is in neutral territory.
The average price target assigned by the average number of analysts to a stock is a way to gauge worth of any stock in next 52 weeks. And in assigning price target to a stock, some analysts adopt a bearish approach by advocating lower-than-average price target which in this case is $15.00 while some adopt bullish approach by assigning higher-than-average price target which reads the price to top $25.00. Average price target assigned by them is $19.20 which highlights an upside potential of 70.31% for the stock over that period. And to attain the median price target of $18.00 assigned by those analysts, stock has to add about 68.33% of value to its current levels.
The company’s shares got several price updates from the analyst firms in past one month and most recent of them is from the Oppenheimer which upgraded the stock as “Outperform” in its note to investors issued on March 02, 2022, recommending a price target of $30 for it. Goldman upgraded its recommendation for the stock as a “Buy” from “Neutral” on September 22, 2021 while assigning a price target range of $35-$43.
Over the week, PMVP’s stock price is moving 4.01% up while it is -26.26% when we observe its performance for the past one month. Year-to-date it is -34.48% down and over the past year, the stock is showing a downside performance of -66.59%.
The latest quarterly earnings report issued by the company was for quarter ended 9/29/2022, when its quarterly earnings per share (EPS) of -$0.4 beat the consensus estimate of -$0.42 for the same. The company is expected to be releasing its next quarterly report in 05/11/2023, for which analysts forecasted an EPS of -$0.44 while estimate for next year EPS is -$1.64. For PMVP, analysts are forecasting an EPS-growth rate of -28.10% for current year and estimate for EPS growth in next year is -20.10%.
Currently, PMV Pharmaceuticals Inc.’s total number of outstanding shares is 45.71M with 2.07% of that held by the insiders while 133.34% of its common stock has been owned by the institutions. Company’s return on equity (ROE) at -27.30%. Stock has a price to book (P/B) ratio of 1.06. Its return on asset (ROA) is -25.00% on average.
A filing at the U.S. Securities and Exchange Commission revealed that SPDR S&P Biotech ETF came shrinking its share ownership by -0.88% in the PMV Pharmaceuticals Inc. (PMVP) decreasing its stake to 4.88% with control over 19830.0 shares in the company.
Leave a Reply